Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Slovenian Journal of Public Health
Volume 60 (2021): Issue 4 (December 2021)
Open Access
Relationship between quality of life indicators and cardiac status indicators in chemotherapy patients
Blaž Matija Geršak
Blaž Matija Geršak
,
Andreja Kukec
Andreja Kukec
,
Henning Steen
Henning Steen
,
Moritz Montenbruck
Moritz Montenbruck
,
Maja Šoštarič
Maja Šoštarič
,
Arne Kristian Schwarz
Arne Kristian Schwarz
,
Sebastian Esch
Sebastian Esch
,
Sebastian Kelle
Sebastian Kelle
,
Sorin Giusca
Sorin Giusca
,
Grigorios Korosoglou
Grigorios Korosoglou
,
Pia Wülfing
Pia Wülfing
,
Susan Dent
Susan Dent
and
Daniel Lenihan
Daniel Lenihan
| Oct 20, 2021
Slovenian Journal of Public Health
Volume 60 (2021): Issue 4 (December 2021)
About this article
Previous Article
Next Article
Abstract
Article
Figures & Tables
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Article Category:
Original scientific article
Published Online:
Oct 20, 2021
Page range:
199 - 209
Received:
Mar 09, 2021
Accepted:
Mar 31, 2021
DOI:
https://doi.org/10.2478/sjph-2021-0028
Keywords
antineoplastic agents
,
cardiotoxicity
,
ventricular function – left
,
ventricular function – right
,
quality of life
,
magnetic resonance imaging
,
cine
,
echocardiography
,
lymphoma
,
Hodgkin disease
,
breast neoplasms
© 2021 National Institute of Public Health, Slovenia, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
EQ-5D questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 2
EQ-5D questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 3
EQ-5D questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 4
SF-36 physical component questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 5
SF-36 physical component questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 6
SF-36 physical component questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 7
SF-36 mental component questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 8
SF-36 mental component questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 9
SF-36 mental component questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Preview